2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - Great Hall BC
Technology and Procedures, Omics Technologies, Bioinformatics, Profiling, Treatment Considerations, Combination Therapy, Biological Processes, Apoptosis, Genomics, Molecular Biology, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, Study Population, Human, Adult
PAPER

669 NRAS switch-II mutations confer inferior outcomes compared to P-loop mutations in acute myeloid leukemia

Kehua Zhou, MD, DPT, Deedra Nicolet, MS2, Danica Wiredja, MD3, Jingjing Zhang, MD, PhD4, Violet Bain5, Cailin Collins, MD, PhD6, Mathew G. Angelos, MD, PhD7, Christine M. McMahon, MD8, Maria Laura Amaya, MD PhD9, Jonathan Gutman, MD10, Amanda Winters, MD, PhD11, Ann-Kathrin Eisfeld, MD12, Daniel Pollyea, MD13, Andrew Kent, MD, PhD14
1 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
2 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
3 University of Colorado Anschutz Medical Campus, Aurora, CO, United States
4 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
5 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
6 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
7 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
8 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
9 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
10 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
11 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
12 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
13 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
14 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

The prognostic impact of NRAS mutations in acute myeloid leukemia (AML) has been ambiguous. In ELN 2022, NRAS mutations were classified as neither favorable nor adverse. By ELN 2024 for hypomethylating agents + venetoclax (HMA+ven) therapy, NRAS and KRAS also fall into the intermediate-risk group, but the differential effect of NRAS vs. KRAS was not defined. In other studies, while KRAS was definitively associated with poor outcomes, NRAS was not. Similarly, for patients who receive intensive chemotherapy (IC), KRAS, but not NRAS, is associated with worse outcomes. Because NRAS mutations occur in two biologically distinct domains– the phosphate-binding loop (P-loop; G12/G13), which mediates GTP binding, and the switch-II domain (Q61), which mediates downstream signaling, we hypothesized that there might be a differential prognostic impact of these NRAS mutation variants clouding prior gene-level analyses.

We retrospectively identified patients with NRAS-mutated AML (by next-generation sequencing, NGS) treated at the University of Colorado and The Ohio State University between 3/17/2016 and 12/9/2025. Extracted data included age, sex, NGS including NRAS codon variant, frontline regimen, ELN 2022 and ELN 2024 risk, transplant status, overall survival (OS), and blood counts.

Patients with P-loop (G12/G13) vs. switch-II (Q61) mutations were compared. Baseline characteristics were analyzed by chi-square and t tests. OS was assessed using Kaplan-Meier and Cox models. Sensitivity analysis stratified by treatment was used to test the interaction between NRAS domain and treatment. Within the HMA+ven subgroup, analyses were repeated in TP53-wild-type patients (ELN 2024 intermediate risk), with median OS descriptively compared across the 4-gene venetoclax-azacitidine classifier groups (Döhner et al., Blood 2024). All analysis was performed using R and SPSS.

A total of 137 patients with P-loop or switch-II NRAS mutations were analyzed (94 P-loop [G12/G13]; 43 switch-II [Q61]; 67 from the University of Colorado and 70 from Ohio State; 57 females [41.6%], 80 males [58.4%]). 42 patients received first-line treatment with HMA+ven, and 95 with IC (7+3 or FLAG-Ida regimens). Baseline characteristics—including age, sex, de novo vs. secondary AML, frontline regimen, ELN 2022 response category, transplant status, and peripheral blood counts at diagnosis—were comparable between groups.

Across the entire cohort, switch-II mutations conferred inferior OS (median 17.0 vs 72.1 months for P-loop; HR 1.90, 95% CI 1.18–3.07; log-rank p = 0.008). The disparity was more pronounced among HMA+ven-treated patients, in whom switch-II median OS was 7.3 vs. 19.9 months for P-loop (HR 2.57, 95% CI 1.18–5.62; log-rank p = 0.014). After controlling for TP53 mutation, the codon-specific disparity persisted and strengthened (HR 3.46, 95% CI 1.50–7.98; log-rank p = 0.002). In the IC-treated patients, switch-II median OS was 25.2 months vs. not reached for P-loop (HR 1.73, 95% CI 0.93–3.20; log-rank p = 0.077).  In the multivariable Cox analysis adjusting for age and ELN 2022 risk, switch-II mutation remained independently associated with inferior OS (HR 1.84, 95% CI 1.12–3.02; p = 0.016). This association was preserved in a treatment-stratified sensitivity analysis (switch-II HR 1.92, 95% CI 1.16–3.15; p = 0.010), with no significant NRAS domain × treatment interaction (p = 0.59), indicating the switch-II disadvantage was not restricted to a single treatment modality. Comparing directly to the reported 4-gene classifier results (Dohner et al, Blood 2024), the HMA+ven switch-II median of 7.3 months approximated the 5.5-month median of the lower-benefit (TP53-mutated) group, whereas the HMA+ven P-loop median of 19.9 months fell between the intermediate-benefit (12.1 months) and higher-benefit/wild-type (26.5 months) groups.

In this two-institution cohort, switch-II (Q61) NRAS mutations independently conferred worse OS than P-loop (G12/G13) mutations. With switch-II OS in HMA+ven-treated patients approximating the TP53-mutated lower-benefit group and P-loop OS the higher-benefit group of the 4-gene classifier, the single ELN 2024 “NRAS = intermediate” designation obscures divergent prognoses. These findings support incorporating NRAS codon position into risk stratification and treatment decisions, and warrant validation in larger prospective cohorts with correlative biology.

 

Kehua Zhou, MD, DPT: No relevant conflicts of interest to declare.